본문 바로가기
KERD
논문KCI 등재

Updated treatment strategies for intestinal Behçet’s disease

천재희|Yong Eun Park
대한내과학회 (The Korean Association Of Internal Medicine)|2018.01|The Korean Journal of Internal Medicine|제33권 제1호|pp. 1-19|DOI https://doi.org/10.3904/kjim.2017.377

2

조회

0

다운로드

5

인용

0

참고문헌

키워드

Biological productsTumor necrosis factor-alphaAdalimumabInfliximabIntestinal Behcet disease
주제분류내과학

초록

Behçet’s disease (BD) is a chronic, idiopathic, relapsing immune-mediated disease involving multiple organs, and is characterized by recurrent oral and genital ulcers, ocular disease, gastrointestinal ulcers, vascular diseases, and skin lesions. In particular, gastrointestinal involvement in BD is followed by severe complications, including massive bleeding, bowel perforation, and fistula, which can lead to significant morbidity and mortality. However, the management of intestinal BD has not yet been properly established. Intestinal BD patients with a severe clinical course experience frequent disease aggravations and often require recurrent corticosteroid and/or immunomodulatory therapies, or even surgery. However, a considerable number of patients with intestinal BD are often refractory to conventional therapies such as corticosteroids and immunomodulators. Recently, there has been a line of evidence suggesting that biologics such as infliximab and adalimumab are effective in treating intestinal BD. Moreover, new biologics targeting proteins other than tumor necrosis factor α are emerging and are under active investigation. Therefore, in this paper, we review the current therapeutic strategies and new clinical data for the treatment of intestinal BD.

Abstract

Behçet’s disease (BD) is a chronic, idiopathic, relapsing immune-mediated disease involving multiple organs, and is characterized by recurrent oral and genital ulcers, ocular disease, gastrointestinal ulcers, vascular diseases, and skin lesions. In particular, gastrointestinal involvement in BD is followed by severe complications, including massive bleeding, bowel perforation, and fistula, which can lead to significant morbidity and mortality. However, the management of intestinal BD has not yet been properly established. Intestinal BD patients with a severe clinical course experience frequent disease aggravations and often require recurrent corticosteroid and/or immunomodulatory therapies, or even surgery. However, a considerable number of patients with intestinal BD are often refractory to conventional therapies such as corticosteroids and immunomodulators. Recently, there has been a line of evidence suggesting that biologics such as infliximab and adalimumab are effective in treating intestinal BD. Moreover, new biologics targeting proteins other than tumor necrosis factor α are emerging and are under active investigation. Therefore, in this paper, we review the current therapeutic strategies and new clinical data for the treatment of intestinal BD.

참고문헌 (113)

  1. Tadakazu Hisamatsu, "Treatment and outcomes: medical and surgical treatment for intestinal Behçet’s disease", Intestinal research, 15(3), pp.318~327 (2017), 대한장연구학회
  2. Cheon JH, "An update on the diagnosis, treatment, and prognosis of intestinal Behcet's disease", Curr Opin Rheumatol, 27, pp.24~31 (2015)[DOI]
  3. 이현정, "Optimal diagnosis and disease activity monitoring of intestinal Behçet’s disease", Intestinal research, 15(3), pp.311~317 (2017), 대한장연구학회
  4. 김덕환, "Intestinal Behçet’s Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis?", Yonsei Medical Journal, 57(1), pp.22~32 (2016), 연세대학교의과대학[DOI]
  5. 박재준, "Outcome Predictors for Intestinal Behçet’s Disease", Yonsei Medical Journal, 54(5), pp.1084~1090 (2013), 연세대학교의과대학[DOI]
  6. Jung YS, "Clinical course of intestinal Behcet's disease during the first five years", Dig Dis Sci, 58, pp.496~503 (2013)[DOI]
  7. Bayraktar Y, "Gastrointestinal manifestations of Behcet's disease", J Clin Gastroenterol, 30, pp.144~154 (2000)[DOI]
  8. Grigg EL, "Mimicry and deception in inflammatory bowel disease and intestinal Behcet disease", Gastroenterol Hepatol (N Y), 8, pp.103~112 (2012)
  9. Jung YS, "Prognostic factors and longterm clinical outcomes for surgical patients with intestinal Behcet's disease", Inflamm Bowel Dis, 17, pp.1594~1602 (2011)[DOI]
  10. Baek SJ, "Surgical treatment and outcomes in patients with intestinal Behcet disease: long-term experience of a single large-volume center", Dis Colon Rectum, 58, pp.575~581 (2015)[DOI]
  11. Hatemi G, "EULAR recommendations for the management of Behcet disease", Ann Rheum Dis, 67, pp.1656~1662 (2008)[DOI]
  12. Kobayashi K, "Development of consensus statements for the diagnosis and management of intestinal Behcet's disease using a modified Delphi approach", J Gastroenterol, 42, pp.737~745 (2007)[DOI]
  13. Hisamatsu T, "The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease: indication of anti-<TEX>$TNF{\alpha}$<", TEX> monoclonal antibodies, 2014, pp.49, 156~162
  14. 이혜원, "The Medical Treatments of Intestinal Behçet’s Disease: An Update", Intestinal research, 11(3), pp.155~160 (2013), 대한장연구학회
  15. Lim WC, "Aminosalicylates for induction of remission or response in Crohn's disease", Cochrane Database Syst Rev, 7 (2016)
  16. Yoo HM, "Clinical features of intestinal Behet's disease and therapeutic effects of sulfasalazine", Korean J Gastroenterol, 29, pp.465~472 (1997)
  17. Matsukawa M, "Endoscopic therapy with absolute ethanol for postoperative recurrent ulcers in intestinal Behcet's disease, and simple ulcers", J Gastroenterol, 36, pp.255~258 (2001)[DOI]
  18. Jung YS, "Longterm clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease", J Clin Gastroenterol, 46, pp.e38~e45 (2012)[DOI]
  19. Hatemi I, "Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet's syndrome: a strobecompliant observational study from a dedicated multidisciplinary center", Medicine (Baltimore), 95, pp.e3348~ (2016)[DOI]
  20. Nakase H, "Therapeutic effects on intestinal Behcet's disease of an intravenous drug delivery system using dexamethasone incorporated in lipid emulsion", J Gastroenterol Hepatol, 16, pp.1306~1308 (2001)[DOI]
  21. Toda K, "Therapeutic effect of intraarterial prednisolone injection in severe intestinal Behcet's disease", J Gastroenterol, 37, pp.844~848 (2002)[DOI]
  22. Yasuo M, "Successful treatment with corticosteroid in a case of Behcet's syndrome with multiple esophageal ulcerations", Intern Med, 42, pp.696~699 (2003)[DOI]
  23. Park JJ, "W1321 long-term clinical outcomes after the first course of corticosteroid therapy in patients with moderate to severe intestinal Behcet's disease", Gastroenterology, 138(5 Suppl 1), pp.S698~S699 (2010)
  24. Choi IJ, "Long-term clinical course and prognostic factors in intestinal Behcet's disease", Dis Colon Rectum, 43, pp.692~700 (2000)[DOI]
  25. Lee HW, "Postoperative effects of thiopurines in patients with intestinal Behcet's disease", Dig Dis Sci, 60, pp.3721~3727 (2015)[DOI]
  26. Jung YS, "Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease", Inflamm Bowel Dis, 18, pp.750~757 (2012)[DOI]
  27. Park MS, "Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance", Dig Dis Sci, 60, pp.195~204 (2015)[DOI]
  28. Matsumura K, "Efficacy of oral tacrolimus on intestinal Behcet's disease", Inflamm Bowel Dis, 16, pp.188~189 (2010)[DOI]
  29. Cantarini L, "Efficacy and safety of intravenous immunoglobulin treatment in refractory Behcet's disease with different organ involvement: a case series", Isr Med Assoc J, 18, pp.238~242 (2016)
  30. Beales IL, "Gastrointestinal involvement in Behcet's syndrome", Am J Gastroenterol, 93, pp.2633~ (1998)
  31. Yasui K, "Thalidomide for treatment of intestinal involvement of juvenileonset Behcet disease", Inflamm Bowel Dis, 14, pp.396~400 (2008)[DOI]
  32. Sayarlioglu M, "Treatment of recurrent perforating intestinal ulcers with thalidomide in Behcet's disease", Ann Pharmacother, 38, pp.808~811 (2004)[DOI]
  33. 이현정, "한국인 베체트 장염 환자에서 Thalidomide의 치료 경험:단일 기관의 초기 경험", Intestinal research, 8(1), pp.63~69 (2010), 대한장연구학회
  34. Sonta T, "The beneficial effect of mesalazine on esophageal ulcers in intestinal Behcet's disease", J Clin Gastroenterol, 30, pp.195~199 (2000)[DOI]
  35. Saleh Z, "Update on the therapy of Behcet disease", Ther Adv Chronic Dis, 5, pp.112~134 (2014)[DOI]
  36. Kaklamani VG, "Behcet's disease", Semin Arthritis Rheum, 27, pp.197~217 (1998)[DOI]
  37. Sakane T, "Behcet's disease", N Engl J Med, 341, pp.1284~1291 (1999)[DOI]
  38. Lopalco G, "Update on the medical management of gastrointestinal Behcet's disease", Mediators Inflamm, 2017, pp.1460491~ (2017)
  39. Narum S, "Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis", BMJ Open, 4, pp.e004587~ (2014)[DOI]
  40. Park J, "Risk factors and outcomes of acute lower gastrointestinal bleeding in intestinal Behcet's disease", Int J Colorectal Dis, 32, pp.745~751 (2017)[DOI]
  41. Sharara AI, "When to start immunomodulators in inflammatory bowel disease?", Dig Dis, 34, pp.125~131 (2016)[DOI]
  42. 김번, "Overlooked Management and Risk Factors for Anemia in Patients with Intestinal Behçet’s Disease in Actual Clinical Practice", Gut and Liver, 9(6), pp.750~755 (2015), 거트앤리버 소화기연관학회협의회
  43. Feuerstein JD, "American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease", Gastroenterology, 153, pp.827~834 (2017)[DOI]
  44. Iwata S, "Efficacy of combination therapy of anti-TNF-<TEX>${\alpha}$<", TEX> antibody infliximab and methotrexate in refractory entero-Behcet's disease, 2011, pp.21, 184~191
  45. Lee JH, "Efficacy of infliximab in intestinal Behcet's disease: a Korean multicenter retrospective study", Inflamm Bowel Dis, 19, pp.1833~1838 (2013)
  46. Nagamu Inoue, "Long-term safety and efficacy of adalimumab for intestinal Behçet’s disease in the open label study following a phase 3 clinical trial", Intestinal research, 15(3), pp.395~401 (2017), 대한장연구학회
  47. Hibi T, "Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study", Medicine (Baltimore), 95, pp.e3863~ (2016)[DOI]
  48. Tanida S, "Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease", Clin Gastroenterol Hepatol, 13, pp.940~948 (2015)[DOI]
  49. Ma D, "Etanercept in the treatment of intestinal Behcet's disease", Cell Biochem Biophys, 69, pp.735~739 (2014)[DOI]
  50. Cantarini L, "Anakinra treatment in drug-resistant Behcet's disease: a case series", Clin Rheumatol, 34, pp.1293~1301 (2015)[DOI]
  51. Vitale A, "Inhibition of interleu-kin-1 by canakinumab as a successful monodrug strategy for the treatment of refractory Behcet's disease: a case series", Dermatology, 228, pp.211~214 (2014)[DOI]
  52. Deroux A, "Tocilizumab in severe and refractory Behcet's disease: four cases and literature review", Semin Arthritis Rheum, 45, pp.733~737 (2016)[DOI]
  53. Hassard PV, "Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report", Gastroen-terology, 120, pp.995~999 (2001)[DOI]
  54. Naganuma M, "Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease", Inflamm Bowel Dis, 14, pp.1259~1264 (2008)[DOI]
  55. Travis SP, "Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody", Gut, 49, pp.725~728 (2001)[DOI]
  56. Byeon JS, "Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behcet's disease: report of a case", Dis Colon Rectum, 50, pp.672~676 (2007)[DOI]
  57. Tanida S, "Long-term efficacy of adalimumab in patients with intestinal Behcet's disease: eight consecutive cases", J Clin Med Res, 8, pp.334~337 (2016)[DOI]
  58. De Cassan C, "Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease", J Crohns Colitis, 5, pp.364~368 (2011)[DOI]
  59. Vitale A, "Adalimumab effectiveness in Behcet's disease: short and long-term data from a multicenter retrospective observational study", Clin Rheumatol, 36, pp.451~455 (2017)[DOI]
  60. Emmi G, "Efficacy and safety profile of anti-interleukin-1 treatment in Behcet's disease: a multicenter retrospective study", Clin Rheumatol, 35, pp.1281~1286 (2016)[DOI]
  61. Kram MT, "Behcet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy. Report of a case", Dis Colon Rectum, 46, pp.118~121 (2003)[DOI]
  62. Ugras M, "Infliximab as an alternative treatment for Behcet disease when other therapies fail", J Pediatr Gastroenterol Nutr, 46, pp.212~215 (2008)[DOI]
  63. Maruyama Y, "A case of intestinal Behcet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years", Intern Med, 51, pp.2125~2129 (2012)[DOI]
  64. Kinoshita H, "Efficacy of infliximab in patients with intestinal Behcet's disease refractory to conventional medication", Intern Med, 52, pp.1855~1862 (2013)[DOI]
  65. Ideguchi H, "Gastrointestinal manifestations of Behcet's disease in Japan: a study of 43 patients", Rheumatol Int, 34, pp.851~856 (2014)[DOI]
  66. Shimizu Y, "Clinical efficacy of adalimumab for a postoperative marginal ulcer in gas-trointestinal Behcet disease", Nihon Shokakibyo Gakkai Zasshi, 109, pp.774~780 (2012)
  67. Jung Hoon Lee, "Remission of intestinal Beh？et's disease treated with anti-tumor necrosis factor α monoclonal antibody (Infliximab)", The Korean Journal of Internal Medicine, 22(1), pp.24~27 (2007), 대한내과학회
  68. Katsuyoshi Matsuoka, "Tacrolimus for the Treatment of Ulcerative Colitis", Intestinal research, 13(3), pp.219~226 (2015), 대한장연구학회
  69. Isaacs A, "Virus interference. I. The interferon", Proc R Soc Lond B Biol Sci, 147, pp.258~267 (1957)[DOI]
  70. Alpsoy E, "Interferon alfa-2a in the treatment of Behcet disease: a randomized place-bo-controlled and double-blind study", Arch Dermatol, 138, pp.467~471 (2002)
  71. Kotter I, "The use of interferon alpha in Behcet disease: review of the literature", Semin Arthritis Rheum, 33, pp.320~335 (2004)[DOI]
  72. Zouboulis CC, "Treatment of Adamantia-des-Behcet disease with systemic interferon alfa", Arch Dermatol, 134, pp.1010~1016 (1998)
  73. Tsambaos D, "Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon", Arch Dermatol Res, 278, pp.335~336 (1986)[DOI]
  74. Grimbacher B, "Loss of vision and diarrhoea", Lancet, 350, pp.1818~ (1997)[DOI]
  75. Monastirli A, "Interferon-<TEX>${\alpha}$<", TEX> treatment for acute myelitis and intestinal involvement in severe Behcet's disease, 2010, pp.103, 787~790
  76. Matsuda S, "Mechanisms of action of cyclosporine", Immunopharmacology, 47, pp.119~125 (2000)[DOI]
  77. Ozdal PC, "Long-term therapy with low dose cyclosporin A in ocular Behcet's disease", Doc Ophthalmol, 105, pp.301~312 (2002)[DOI]
  78. Ozyazgan Y, "Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial", Br J Ophthalmol, 76, pp.241~243 (1992)[DOI]
  79. Hooper JA, "Intravenous immunoglobulins: evolution of commercial IVIG preparations", Immunol Allergy Clin North Am, 28, pp.765~778 (2008)[DOI]
  80. Shek LP, "Thalidomide responsiveness in an infant with Behcet's syndrome", Pediatrics, 103(6), pp.1295~1297 (1999)[DOI]
  81. Kari JA, "Behcet's disease in UK children: clinical features and treatment including thalidomide", Rheumatology (Oxford), 40, pp.933~938 (2001)[DOI]
  82. Moreira AL, "Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation", J Exp Med, 177, pp.1675~1680 (1993)[DOI]
  83. Hatemi I, "TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behcet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature", Clin Exp Rheumatol, 33(6 Suppl 94), pp.S129~S137 (2015)
  84. Atas H, "The effect of colchicine on mean platelet volume in Behcet's disease", Ann Clin Lab Sci, 45, pp.545~549 (2015)
  85. Yurdakul S, "A double-blind trial of colchicine in Behcet's syndrome", Arthritis Rheum, 44, pp.2686~2692 (2001)[DOI]
  86. Aktulga E, "A double blind study of colchicine in Behcet's disease", Haematologica, 65, pp.399~402 (1980)
  87. Hatemi G, "Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease", Ann Rheum Dis, 68, pp.1528~1534 (2009)[DOI]
  88. Soysal T, "Bone marrow transplantation for Behcet's disease: a case report and systematic review of the literature", Rheumatology (Oxford), 53, pp.1136~1141 (2014)[DOI]
  89. Yamato K, "Successful cord blood stem cell transplantation for myelodysplastic syndrome with Behcet disease", Int J Hematol, 77, pp.82~85 (2003)[DOI]
  90. Rossi G, "Autologous hematopoietic stem cell transplantation for severe", refractory intestinal Behcet disease, 2004, pp.103, 748~750
  91. Namba K, "Granulocytapheresis in patients with refractory ocular Behcet's disease", J Clin Apher, 21, pp.121~128 (2006)[DOI]
  92. Gul A, "Behcet's disease: an update on the pathogenesis", Clin Exp Rheumatol, 19(5 Suppl 24), pp.S6~S12 (2001)
  93. Lee CK, "Pathogenesis and treatment of intestinal Behcet's disease", Korean J Gastroenterol, 50, pp.3~8 (2007)
  94. Vallet H, "Efficacy of anti-TNF alpha in severe and", or refractory Behcet's disease: multicenter study of 124 patients, 2015, pp.62, 67~74
  95. Masamichi Kimura, "Usefulness of Adalimumab for Treating a Case of Intestinal Behçet’s Disease With Trisomy 8 Myelodysplastic Syndrome", Intestinal research, 13(2), pp.166~169 (2015), 대한장연구학회
  96. Ishioka M, "Successful treatment with infliximab for refractory paraileostomal ulceration in a patient with Behcet's disease", Clin J Gastroenterol, 8, pp.193~196 (2015)[DOI]
  97. Zou J, "Long-term outcomes and predictors of sustained response in patients with intestinal Behcet's disease treated with infliximab", Dig Dis Sci, 62, pp.441~447 (2017)[DOI]
  98. 박지혜, "Could adalimumab be used safely and effectively in intestinal Behçet’s disease refractory to conventional therapy?", Intestinal research, 15(3), pp.263~265 (2017), 대한장연구학회
  99. Kai-Chun Wu, "Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn’s disease", Intestinal research, 14(2), pp.152~163 (2016), 대한장연구학회
  100. Haraoui B, "Etanercept in the treatment of rheumatoid arthritis", Ther Clin Risk Manag, 3, pp.99~105 (2007)[DOI]
  101. Cantarini L, "Safety and efficacy of etanercept in children with juvenileonset Behcets disease", Int J Immunopathol Pharmacol, 22, pp.551~555 (2009)[DOI]
  102. Sandborn WJ, "Etanercept for active Crohn's disease: a randomized, double-blind, place-bo-controlled trial", Gastroenterology, 121, pp.1088~1094 (2001)[DOI]
  103. Van den Brande JM, "Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease", Gastroenterology, 124, pp.1774~1785 (2003)[DOI]
  104. O'Toole A, "Inflammatory bowel dis-ease provoked by etanercept: report of 443 possible cases combined from an IBD referral center and the FDA", Dig Dis Sci, 61, pp.1772~1774 (2016)[DOI]
  105. Mertens M, "Anakinra for rheumatoid arthritis", Cochrane Database Syst Rev, (1) (2009)
  106. Zou J, "Interleukin-1-related genes polymorphisms in Turkish patients with Behcet disease: a meta-analysis", Mod Rheumatol, 24, pp.321~326 (2014)[DOI]
  107. Koryurek OM, "A new alternative therapy in dermatology: tocilizumab", Cutan Ocul Toxicol, 35, pp.145~152 (2016)
  108. Hamzaoui K, "Cytokine profile in Behcet's disease patients. Relationship with disease activity", Scand J Rheumatol, 31, pp.205~210 (2002)[DOI]
  109. Coskun M, "Novel targeted therapies for inflammatory bowel disease", Trends Pharmacol Sci, 38, pp.127~142 (2017)[DOI]
  110. Danese S, "764 Results of andante, a randomized clinical study with an anti-IL6 an-tibody (PF-04236921) in subjects with Crohn's disease who are anti-TNF inadequate responders", Gastroenterology, 150(4 Suppl 1), pp.S155~ (2016)
  111. Kuhn KA, "IL-6 stimulates intestinal epithelial proliferation and repair after injury", PLoS One, 9, pp.e114195~ (2014)[DOI]
  112. Yazici Y, "Behcet's syndrome", Curr Rheumatol Rep, 12, pp.429~435 (2010)[DOI]
  113. 이승우, "The Prevalence and Clinical Characteristics of Esophageal Involvement in Patients with Behçet’s Disease: A Single Center Experience in Korea", Journal of Korean Medical Science, 24(1), pp.52~56 (2009), 대한의학회

관련 논문AI추천

Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease박지혜, 천재희거트앤리버 소화기연관학회협의회 · Gut and Liver2018 · 제12권 제6호Outcome Predictors for Intestinal Behçet’s Disease김원호, 박재준, 천재희연세대학교의과대학 · Yonsei Medical Journal2013 · 제54권 제5호Risk Factors for Surgery in Patients with Intestinal Behçet’s Disease During Anti-Tumor Necrosis Factor-Alpha Therapy강은애, 김원호, 김태일, 박수정, 박재준, 박지혜, 천재희, 한소정연세대학교의과대학 · Yonsei Medical Journal2023 · 제64권 제2호Efficacy and Safety of Anti-Tumor Necrosis Factor- Alpha Agents for Patients with Intestinal Behcet’s Disease: A Systematic Review and Meta-AnalysisChunyan Ma, Meiqi Li, Qingfeng Zhang, Qingrui Yang, Rongrong Dong, Weizhen Xiang, Zhenzhen Ma연세대학교의과대학 · Yonsei Medical Journal2022 · 제63권 제2호Clinical Course of Patients with Intestinal Behçet’s Disease According to Consensus-Based Diagnostic CategoriesChoi Hwang, Choi Myung-Gyu, Cho Young-Seok, Joo Yu Young, Kim Jin Su, Kim Sang Woo, Kim Seung-Jun, Lee Bo-In, Lee Han Hee, Lee Kang Moon, Park Jae Myung거트앤리버 소화기연관학회협의회 · Gut and Liver2022 · 제16권 제5호Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN)김주성, 송근암, 신성재, Cheon Jae Hee, Han Dong Soo, Kim Hyun-Soo, Kim Sung Kook, Kim Won Ho, Kim Youngdoe, Lee Yoosun, Lee YoungJa, Ye Byong Duk거트앤리버 소화기연관학회협의회 · Gut and Liver2023 · 제17권 제5호

이 간행물의 다른 논문 (28건)

Novel treatments for inflammatory bowel diseaseHyo Sun Lee, Dong Il Park, Soo-Kyung Parkpp. 20-27Changing treatment paradigms for the management of inflammatory bowel diseaseJong Pil Im, You Sun Kim, Byong Duk Ye, Joo Sung Kimpp. 28-35Present status and perspectives of endosonography 2017 in gastroenterologyChristoph F. Dietrich, Barbara Braden, Christian Jenssen, Michael Hockepp. 36-63Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activityMin-Sun Kwak, Donghee Kimpp. 64-74Physical activity in chronic obstructive pulmonary disease: clinical impact and risk factorsKyeong-Cheol Shin, M.D.pp. 75-77
원문 보기